Form 4: 2seventy bio CFO Victoria Eatwell Disposes of Shares and Options in Merger with Bristol-Myers Squibb

Victoria Eatwell, CFO of 2seventy bio, reports the disposal of shares and options following the merger with Bristol-Myers Squibb, where 2seventy bio became a wholly-owned subsidiary.

Summary

• Victoria Eatwell, the Chief Financial Officer of 2seventy bio, filed a Form 4 detailing changes in beneficial ownership of the company's securities.
• The filing reports transactions related to the merger between 2seventy bio and Bristol-Myers Squibb Company, which became effective on May 13, 2025.
• As part of the merger agreement, Eatwell disposed of 401,111 shares of common stock.
• Additionally, 43,276 shares were disposed of as restricted stock units (RSUs) that vested and were converted into cash.
• Eatwell also disposed of stock options with exercise prices of $3.97 and $2.64, which were converted into the right to receive cash equal to the excess of the merger consideration ($5.00) over the exercise price.
• The merger consideration was $5.00 per share in cash, subject to applicable tax withholdings.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as the merger provides a defined cash value for shareholders and option holders, resolving uncertainty about the company's future as a standalone entity.

Positives

• The merger provided a cash payout of $5.00 per share for common stock and RSUs.
• Outstanding stock options with exercise prices below the merger consideration resulted in a cash payment to the option holders.

Future Outlook

The company is now a wholly-owned subsidiary of Bristol-Myers Squibb, and will no longer operate as an independent publicly traded entity.

Industry Context

This announcement reflects the ongoing consolidation in the biotechnology industry, where larger pharmaceutical companies acquire smaller firms with promising technologies or drug candidates.

Comparison to Industry Standards

• Mergers and acquisitions are common in the biotech industry, with deal terms varying based on the target company's pipeline, technology, and financial performance.
• The $5.00 per share merger consideration is within the typical range for acquisitions of biotech companies with similar market capitalization and development stage.

Stakeholder Impact

• Shareholders received $5.00 per share in cash.
• Option holders with exercise prices below $5.00 received a cash payment equal to the difference.
• Employees may experience changes as the company integrates into Bristol-Myers Squibb.

Key Dates

Keywords

Merger, 2seventy bio, Bristol-Myers Squibb, Victoria Eatwell, Form 4, Beneficial Ownership, Stock Options, RSUs, Acquisition